German Bayer AG opens first Co.Lab life science incubator in Cambridge/Boston. This comprises state-of-the-art laboratories and collaborative workspaces specifically designed to support entrepreneurs focused on developing cell and gene therapies.
The BioRN Life Science cluster Rhine-Neckar has set the right course to further accelerate the start-up dynamic. Several lighthouse projects have been established recently, fostering innovation and providing the ideal breeding ground for biotech projects. Joint forces now develop strategies to attract investors and increase the visibility of the start-up community. The Life Science Investors´ Day Heidelberg has established itself as a top-class platform.
2. BIOTECH CIRCLE – Almost twice as many visitors as at last years premiere were welcomed by Biotech Austrias Chairman Peter Llewellyn-Davies in the Vienna Stock Exchange in April. Framed by a Flying Breakfast, the topic was the provocative question Science always wins?!
The region regulated by the European Medicines Agency (EMA) has been the most proactive globally in the early adoption of biosimilars. By February 2023, it had approved around 75 products containing them. The distribution of such compounds within Europe, however, has been uneven, with some countries offering more market opportunities than others. Beyond Europe, few producers have a strategy for the Middle East and/or Africa, and India and South Korea could soon jump in to fill the gap.
A UK Biobank analysis of data from 200,000 people over more than ten years,
carried out by British researchers, have linked consumption of ultra-processed foods to an
increased risk of developing and dying from cancer. However, according to the authors from
Imperial College London it doesnt provide a causal relationship.
The switch from lab-scale to industrial-scale AAV production requires deep hands-on expertise in various technological solutions, their limitations, and their suitability for GMP large-scale manufacturing. Direct application of lab-scale process leads to expensive AAV-based products and unnecessarily laborious industrial processes. The complexity and growing demands for controllable critical quality attributes (CQAs), create a challenging blend.
Biomanufacturing?Implementing high-quality process development that considers GMP manufacturing from the start is critical to reducing costs and timeline disruptions associated with raw material supply chain insecurity, adhering to regulatory compliance, and avoiding process re-design at a later stage.
Biotech innovator Biosyntia ApS, the latest addition to the ECBF, is applying proprietary biological processes to produce sustainable nutritional ingredients – a mission that has captured the imagination of seasoned biotech investors and major ingredient players.
Swedens Belach Bioteknik has been partnering mostly with researchers and pharma customers to design suited bioreactor systems for biomanufacturing. Most recently, the company has entered the growing cultured meat sector, in which many companies are currently scaling up their production and thus need expertise to get optimal results.
The Berlin-Brandenburg capital region is one of the leading life science regions in Europe and a lot is being done to keep it that way: with a wide variety of space offerings and support programs for founders and start-ups.